Veracyte Announces Acquisition of C2i Genomics

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announces it has reached a definitive agreement to acquire C2i Genomics, Inc. a minimal residual disease (MRD) detection company, adding whole-genome MRD capabilities to its novel diagnostics platform and positioning Veracyte to expand its offerings along the cancer care continuum. Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election.

Read the full article: Veracyte Announces Acquisition of C2i Genomics //

Source: https://www.businesswire.com/news/home/20240108004593/en/Veracyte-Announces-Preliminary-Full-Year-2023-Results-Acquisition-of-C2i-Genomics-to-Add-Minimal-Residual-Disease-Capabilities-to-Its-Novel-Diagnostics-Platform

Leave a Comment

Your email address will not be published.

Scroll to Top